Low-carbohydrate and Ketogenic Diets: a Scoping Review of Neurological and Inflammatory Outcomes in Human Studies and Their Relevance to Chronic Pain
Overview
Affiliations
Dietary restriction of carbohydrate has been demonstrated to be beneficial for nervous system dysfunction in animal models and may be beneficial for human chronic pain. The purpose of this review is to assess the impact of a low-carbohydrate/ketogenic diet on the adult nervous system function and inflammatory biomarkers to inform nutritional research for chronic pain. An electronic database search was carried out in May 2021. Publications were screened for prospective research with dietary carbohydrate intake <130 g per day and duration of ≥2 weeks. Studies were categorised into those reporting adult neurological outcomes to be extracted for analysis and those reporting other adult research outcomes. Both groups were screened again for reported inflammatory biomarkers. From 1548 studies, there were 847 studies included. Sixty-four reported neurological outcomes with 83% showing improvement. Five hundred and twenty-three studies had a different research focus (metabolic = 394, sport/performance = 51, cancer = 33, general = 30, neurological with non-neuro outcomes = 12, or gastrointestinal = 4). The second screen identified sixty-three studies reporting on inflammatory biomarkers, with 71% reporting a reduction in inflammation. The overall results suggest a favourable outcome on the nervous system and inflammatory biomarkers from a reduction in dietary carbohydrates. Both nervous system sensitisation and inflammation occur in chronic pain, and the results from this review indicate it may be improved by low-carbohydrate nutritional therapy. More clinical trials within this population are required to build on the few human trials that have been done.
Wiggins A, Strath L, McPherson G, Gower B, Goss A, Goodin B BMC Musculoskelet Disord. 2024; 25(1):1043.
PMID: 39702235 PMC: 11660617. DOI: 10.1186/s12891-024-08170-x.
Ketogenic effect of coconut oil in ALS patients.
Carrera-Julia S, Obrador E, Lopez-Blanch R, Oriol-Caballo M, Moreno-Murciano P, Estrela J Front Nutr. 2024; 11:1429498.
PMID: 39086545 PMC: 11289842. DOI: 10.3389/fnut.2024.1429498.
Prins P, Noakes T, Buga A, DAgostino D, Volek J, Buxton J Front Nutr. 2023; 10:1084021.
PMID: 36845048 PMC: 9946985. DOI: 10.3389/fnut.2023.1084021.
Maddox E, Massoni S, Hoffart C, Takata Y Nutrients. 2023; 15(3).
PMID: 36771421 PMC: 9921865. DOI: 10.3390/nu15030716.
The Influence of the Ketogenic Diet on the Immune Tolerant Microenvironment in Glioblastoma.
Kesarwani P, Kant S, Zhao Y, Miller C, Chinnaiyan P Cancers (Basel). 2022; 14(22).
PMID: 36428642 PMC: 9688691. DOI: 10.3390/cancers14225550.